Protagonist Therapeutics, Inc. (PTGX)
Market Cap | 1.61B |
Revenue (ttm) | 859,000 |
Net Income (ttm) | -140.19M |
Shares Out | 57.25M |
EPS (ttm) | -2.85 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 725,404 |
Open | 27.58 |
Previous Close | 27.49 |
Day's Range | 27.24 - 28.26 |
52-Week Range | 6.91 - 28.26 |
Beta | 1.95 |
Analysts | Strong Buy |
Price Target | 33.00 (+17.02%) |
Earnings Date | May 4, 2023 |
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinica... [Read more]
Financial Performance
In 2022, PTGX's revenue was $26.58 million, a decrease of -2.84% compared to the previous year's $27.36 million. Losses were -$127.39 million, 1.47% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $33.0, which is an increase of 17.02% from the latest price.
News

Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
NEWARK, CA / ACCESSWIRE / June 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113
Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases NEWARK, Calif. , May 12, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Pro...

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference
NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association
NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data from the REVIVE study of rusfertide in polyc...

Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
Announced positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), a first-in-class oral peptide for the treatment of moderate-to-severe plaque psoriasis; additional ...

Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering o...

Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that it has commenced an underwritten public offering of $100 million ...

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically ...

Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Rusfertide met the study's primary endpoint, with a statistically significant higher number of responders on rusfertide versus placebo (p=0.0003) Rusfertide continues to be generally well tolerated wi...

Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
JNJ-2113 (formerly PN-235) met the study's primary endpoint, with a statistically significantly higher proportion of adult patients with moderate-to-severe plaque psoriasis achieving PASI-75 in all tr...

Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEWARK, Calif. , Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
NEWARK, Calif. , Dec. 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif. , Nov. 16, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2022, it issued inducement awards to Arturo Molina, M.D.

Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution of Phase 3 VERIFY study of rusfertide in polycythemia vera Arturo Molina, M.D., M.S. named Chief Medical Officer, providing medical, clinical development, and strategic leadership ...

Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting
NEWARK, Calif. , Nov. 3, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that three abstracts related to the Company's rusfertide program...

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P.
Accomplished hematologist-oncologist will provide medical, clinical development, and strategic operational leadership to the ongoing rusfertide Phase 3 development program NEWARK, Calif. , Nov. 2, 202...

Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV at the 2022 ASCO Annual Meeting and the EHA20...

Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
NEWARK, Calif. , June 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspension restored therapeutic benefits including hematocrit control, reduced...

A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.

ROSEN, A TOP RANKED FIRM, Encourages Protagonist Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PTGX
New York, New York--(Newsfile Corp. - May 17, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Pr...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX
NEW YORK , May 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX). Such investors ...

Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focus Presented topline results from the Phase 2 IDEAL study of PN-943...

Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - April 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pr...

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - April 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pro...